The UK NCRI MAGIC Trial of Perioperative Chemotherapy in Resectable Gastric Cancer: Implications for Clinical Practice by unknown
Editorial
The UK NCRI MAGIC Trial of Perioperative Chemotherapy
in Resectable Gastric Cancer: Implications for Clinical
Practice
Yu Jo Chua, MBBS, and David Cunningham, MD, FRCP
Department of Medicine, Royal Marsden Hospital, Surrey and London, United Kingdom
The 503-patient United Kingdom National Cancer
Research Institute (NCRI) Medical Research Council
Adjuvant Gastric Infusional Chemotherapy (MA-
GIC) trial is the ﬁrst randomized trial to demonstrate
a conclusive survival beneﬁt from the use of periop-
erative chemotherapy for patients with resectable
adenocarcinoma of the stomach, gastroesophageal
junction, and lower esophagus, compared with sur-
gery alone.1 In the intention-to-treat (ITT) analysis,
patients who received perioperative chemotherapy
with the ECF regimen (epirubicin, cisplatin, and
continuous infusion 5-ﬂuorouracil, 5FU) had a 5-
year survival of 36%, compared with 23% in patients
treated with surgery alone (hazard ratio for death,
0.75; 95% conﬁdence interval, 0.60–0.93; P = 0.009).
Progression-free survival was also improved by peri-
operative chemotherapy (hazard ratio for progres-
sion, 0.66; 95% confidence interval, 0.53–0.81; P <
.001). These results support the use of this treatment
strategy as an option for patients with resectable
gastric cancer as an alternative to postoperative
chemoradiotherapy, which has been shown in a pre-
vious randomized trial (the US Intergroup 0116 trial,
INT 0116) to also be of benefit in these patients, and
are expected to influence the standard treatment of
this disease particularly in the UK and Europe.2
The positive results of this trial are consistent with
the results seen in several randomized trials of the
ECF chemotherapy regimen in the advanced disease
setting.3–6 Even though it was originally developed in
the 1980s, this regimen has repeatedly been shown to
be both efﬁcacious and well tolerated and has not
been bettered by modiﬁcations to the triplet combi-
nation. The main drawback of ECF is the continuous
infusion 5FU, which requires long-term intravenous
access (e.g., Hickmans line or similar) and an infu-
sion pump. These are associated with a risk of line-
related complications and inconvenience to patients.
The MAGIC trial study design and results have
attracted several criticisms, many of which reﬂect
diﬃculties inherent to the group of patients targeted
by the trial or period during which the trial was open
to recruitment (1994–2002).7–12 These include the
lack of detailed preoperative local staging, the type of
surgery performed, poor rates of commencement and
completion of postoperative chemotherapy, and the
limited ability to perform subgroup analyses on the
results of the trial.
LACK OF DETAILED PREOPERATIVE LOCAL
STAGING
Briasoulis and colleagues have lamented the lack of
survival outcome data for patients in the MAGIC
trial by disease stage.12 Citing previous reports of the
excellent survival of the cohort of patients with
resected gastric cancer who are lymph node negative
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on histopathology examination, the authors propose
that this information may be useful in limiting the use
of perioperative chemotherapy to patients with more
locally advanced tumors while sparing those with
early-stage disease from additional treatment as is the
case with localized colon cancer. In contrast with
good results seen with surgery alone in the Far East,
it is questionable whether these outcomes can be
generalized to patients in the West. For example, in a
report from the US National Cancer Data Base on
patients undergoing gastrectomy in 1985–1995, pa-
tients with TNM stage II disease were reported to
have a 5-year survival rate of only 34%.13 Critics may
attribute the poor outcome observed to suboptimal
surgical technique, in particular with regard to the
extent of lymph node dissection, but trials evaluating
gastrectomies with so-called D1 and D2 lymph node
dissections conducted in the West have not shown a
survival advantage with more extensive surgery.14 In
addition, an update of the results of US INT 0116
reported no signiﬁcant interaction between T- or N-
stage and treatment outcome in an exploratory sub-
group analysis.15 Considering the relatively poor
outcome of patients with resected gastric tumors,
even those with stage II disease, a worthwhile beneﬁt
from perioperative treatment can still be expected.
All of the published reports of the outcomes of
patients with resected gastric cancer by stage have
stratiﬁed patients using histopathological staging.
While histopathology remains the gold standard for
staging the extent of disease, its prognostic value in
patients who have received preoperative treatment
has not been validated, and its clinical utility is
limited at the time of diagnosis (prior to resection),
which is precisely when clinicians must decide be-
tween recommending a perioperative strategy or
proceeding directly to surgery. Whereas endoscopic
ultrasound (EUS) is proving to be increasingly
useful for local staging of gastric tumors, its use and
availability is not yet universal. Computed tomog-
raphy (CT), while useful for excluding distant
metastasis, is less accurate for local staging. Al-
though now commonly available in the United
Kingdom, EUS was not widely available when the
MAGIC trial was conducted and so could not be
included as a requirement of the study protocol.
Our ability to tailor treatments to individual patient
and disease requirements is limited, at least based
on pretreatment staging methods available even
today. This is undoubtedly an area of great
importance and will become more clinically relevant




The diﬃculties of delivering postoperative treat-
ment in patients undergoing gastrectomy are reﬂected
in the fact that only 55% of the patients randomized to
perioperative chemotherapy actually commenced
treatment after surgery, and only 42% of the 250
completed all six cycles of protocol chemotherapy.1
Upper gastrointestinal surgery is a major invasive
procedure often associated with a prolonged recovery,
which is compounded by these patients being already
debilitated by tumor-related symptoms or compro-
mised by comorbidities. True to the aggressive nature
of gastric cancer, early progression of disease is also a
well-known problem. Indeed, the most common rea-
son for not commencing postoperative treatment in
the MAGIC trial was disease progression or early
death. This aspect of the trial is one major difference
from US INT 0116, in which patients were random-
ized between 20 and 40 days after curative surgery was
performed, thus potentially selecting for a better pa-
tient cohort in terms of recovery from surgery and
also for being free of early disease relapse.2 This is also
the main reason that the results of the two trials
should not be compared. In US INT 0116, 64% of the
281 patients randomized to postoperative chemora-
diotherapy completed protocol treatment, the pre-
dominant reason for early treatment cessation being
treatment-related toxicity (17% of 281).
A frequently raised question is whether given the
survival improvement seen in MAGIC despite the
poor rate of completion of protocol treatment, the
beneﬁt observed largely is from the three cycles of
chemotherapy given preoperatively. A related ques-
tion is whether postoperative treatment can be omit-
ted altogether. Although tempting, performing an
analysis to address these issues would be inappropri-
ate as it is likely to be heavily biased. For example,
restricting an analysis for survival to only the cohort
of patients who completed all six cycles of treatment
would select for patients predisposed toward a better
outcome for reasons other than the eﬃcacy of treat-
ment since many of the patients not included would
have been excluded for disease-related factors.
THE LIMITATIONS OF SUBGROUP
ANALYSES
The MAGIC trial was powered to show survival
beneﬁt in the overall treatment cohort and was not
designed with the expectation that signiﬁcant results
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would be found for any of the subgroups of patients,
nor would it have been practical to increase recruit-
ment to allow for such subgroup analyses.1,16 As it is,
the trial took almost 8 years to complete accrual.
Similarly, US INT 0116 recruited 556 eligible patients
over a 7-year period, both trials illustrating the
challenge recruiting patients to these type of clinical
trials.2 Indeed, a Dutch trial of preoperative chemo-
therapy that was initiated at the same time as MA-
GIC only recruited 59 patients over 2.5 years and was
closed prematurely when an early interim analysis
prompted by the slow accrual found the trial was
unlikely to meet its objective of improving the cura-
tive resection rate.17
Any subgroup analyses performed within the
MAGIC trial should be exploratory only and should
certainly not be the basis for recommending standard
treatments, whether on the basis of stage grouping, or
with regard to the need for postoperative chemo-
therapy. The ITT analysis performed is the more
appropriate estimate of the overall eﬀect of treat-
ment.16,18
THE NEXT RANDOMIZED TRIAL OF
PERIOPERATIVE TREATMENT: UK NCRI ST03
The follow-on study for MAGIC, to be known as
the UK NCRI ST03 trial, is expected to open to ac-
crual in the second quarter of 2007. This trial, which
will be UK-led, will be open to the participation of
international sites and aims to recruit a total of 1100
patients with resectable adenocarcinoma of the
stomach or gastroesophageal junction (Siewert type
III only) who will be randomized to perioperative
chemotherapy with ECX (epirubicin, cisplatin, and
capecitabine) or the same plus the antivascular
endothelial growth factor (VEGF) monoclonal anti-
body bevacizumab. ECX has been chosen as the
chemotherapy for this study because of the conve-
nience of the oral administration of capecitabine,
which replaces the 5FU and the associated require-
ment for intravenous lines and infusion pumps. It is
hoped this will improve the acceptability of treatment
to patients. The results of the recently reported
REAL2 advanced disease trial have also shown that
this substitution can be made without compromising
the eﬃcacy or safety of the regimen.6 Bevacizumab is
a targeted agent that has proven beneﬁt in several
solid tumor types including colorectal, breast, and
non-small cell lung cancer. A phase II trial in gastric
cancer with cisplatin and irinotecan has reported
promising results.19 The beneﬁts of using
bevacizumab in the context of perioperative chemo-
therapy may be to improve the response rates to
chemotherapy and to more effectively treat microm-
etastatic disease, which is undoubtedly the cause of
disease relapse in these patients despite apparently
complete resections.
Because of the eﬀects of VEGF on angiogenesis, an
important component of the wound healing process,
there is a theoretical risk of increased perioperative
complications with the addition of bevacizumab to
treatment. A mandatory interval of 8 weeks between
the last dose of bevacizumab and surgery is speciﬁed
in the protocol (equivalent to 5–6 weeks from the last
dose of capecitabine) to minimize this risk. Similarly,
postoperative bevacizumab is not recommenced until
a minimum of 6 weeks has elapsed. As there have
been no direct trials evaluating the effects of anti-
VEGF treatment on perioperative complications,
these intervals were derived from experience from the
randomized trials already conducted and on expert
opinion.20,21 It is noteworthy that similar breaks from
treatment were speciﬁed in the MAGIC trial so that
in fact these recommendations will not amount to a
change from current practice.
CONCLUSIONS—IMPLICATIONS FOR
STANDARD PRACTICE
Based on the results of MAGIC, perioperative
chemotherapy with ECF (or ECX) should be con-
sidered a standard treatment option for patients with
resectable gastric cancer. There is, however, no evi-
dence to suggest that either perioperative chemo-
therapy or postoperative chemoradiotherapy is
superior. A signiﬁcant factor that will likely deter-
mine the preferred strategy is the referral patterns
that are prevalent in a given center. For perioperative
chemotherapy to be feasible, patients must be
referred to an oncologist prior to surgery so that
consideration can be given to this strategy. In the
United Kingdom, this management pathway is well
suited to the requirement that the management of all
new patients is discussed by an appropriately quali-
ﬁed multidisciplinary team, in this case consisting of
specialist oncologists, surgeons, gastroenterologists,
radiologists, and pathologists.
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